Cargando…
Fetuin‐A, inter‐α‐trypsin inhibitor, glutamic acid and ChoE (18:0) are key biomarkers in a panel distinguishing mild from critical coronavirus disease 2019 outcomes
| Autores principales: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8787095/ https://www.ncbi.nlm.nih.gov/pubmed/35075803 http://dx.doi.org/10.1002/ctm2.704 |
| _version_ | 1784639285411971072 |
|---|---|
| author | Reverté, Laia Yeregui, Elena Olona, Montserrat Gutiérrez‐Valencia, Alicia Buzón, Maria José Martí, Anna Gómez‐Bertomeu, Frederic Auguet, Teresa López‐Cortés, Luis F. Burgos, Joaquin Benavent‐Bofill, Clara Boqué, Carme García‐Pardo, Graciano Ruiz‐Mateos, Ezequiel Mestre, Maria Teresa Vidal, Francesc Viladés, Consuelo Peraire, Joaquim Rull, Anna |
| author_facet | Reverté, Laia Yeregui, Elena Olona, Montserrat Gutiérrez‐Valencia, Alicia Buzón, Maria José Martí, Anna Gómez‐Bertomeu, Frederic Auguet, Teresa López‐Cortés, Luis F. Burgos, Joaquin Benavent‐Bofill, Clara Boqué, Carme García‐Pardo, Graciano Ruiz‐Mateos, Ezequiel Mestre, Maria Teresa Vidal, Francesc Viladés, Consuelo Peraire, Joaquim Rull, Anna |
| author_sort | Reverté, Laia |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8787095 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | John Wiley and Sons Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-87870952022-01-31 Fetuin‐A, inter‐α‐trypsin inhibitor, glutamic acid and ChoE (18:0) are key biomarkers in a panel distinguishing mild from critical coronavirus disease 2019 outcomes Reverté, Laia Yeregui, Elena Olona, Montserrat Gutiérrez‐Valencia, Alicia Buzón, Maria José Martí, Anna Gómez‐Bertomeu, Frederic Auguet, Teresa López‐Cortés, Luis F. Burgos, Joaquin Benavent‐Bofill, Clara Boqué, Carme García‐Pardo, Graciano Ruiz‐Mateos, Ezequiel Mestre, Maria Teresa Vidal, Francesc Viladés, Consuelo Peraire, Joaquim Rull, Anna Clin Transl Med Letter to Editor John Wiley and Sons Inc. 2022-01-24 /pmc/articles/PMC8787095/ /pubmed/35075803 http://dx.doi.org/10.1002/ctm2.704 Text en © 2022 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Letter to Editor Reverté, Laia Yeregui, Elena Olona, Montserrat Gutiérrez‐Valencia, Alicia Buzón, Maria José Martí, Anna Gómez‐Bertomeu, Frederic Auguet, Teresa López‐Cortés, Luis F. Burgos, Joaquin Benavent‐Bofill, Clara Boqué, Carme García‐Pardo, Graciano Ruiz‐Mateos, Ezequiel Mestre, Maria Teresa Vidal, Francesc Viladés, Consuelo Peraire, Joaquim Rull, Anna Fetuin‐A, inter‐α‐trypsin inhibitor, glutamic acid and ChoE (18:0) are key biomarkers in a panel distinguishing mild from critical coronavirus disease 2019 outcomes |
| title | Fetuin‐A, inter‐α‐trypsin inhibitor, glutamic acid and ChoE (18:0) are key biomarkers in a panel distinguishing mild from critical coronavirus disease 2019 outcomes |
| title_full | Fetuin‐A, inter‐α‐trypsin inhibitor, glutamic acid and ChoE (18:0) are key biomarkers in a panel distinguishing mild from critical coronavirus disease 2019 outcomes |
| title_fullStr | Fetuin‐A, inter‐α‐trypsin inhibitor, glutamic acid and ChoE (18:0) are key biomarkers in a panel distinguishing mild from critical coronavirus disease 2019 outcomes |
| title_full_unstemmed | Fetuin‐A, inter‐α‐trypsin inhibitor, glutamic acid and ChoE (18:0) are key biomarkers in a panel distinguishing mild from critical coronavirus disease 2019 outcomes |
| title_short | Fetuin‐A, inter‐α‐trypsin inhibitor, glutamic acid and ChoE (18:0) are key biomarkers in a panel distinguishing mild from critical coronavirus disease 2019 outcomes |
| title_sort | fetuin‐a, inter‐α‐trypsin inhibitor, glutamic acid and choe (18:0) are key biomarkers in a panel distinguishing mild from critical coronavirus disease 2019 outcomes |
| topic | Letter to Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8787095/ https://www.ncbi.nlm.nih.gov/pubmed/35075803 http://dx.doi.org/10.1002/ctm2.704 |
| work_keys_str_mv | AT revertelaia fetuinainteratrypsininhibitorglutamicacidandchoe180arekeybiomarkersinapaneldistinguishingmildfromcriticalcoronavirusdisease2019outcomes AT yereguielena fetuinainteratrypsininhibitorglutamicacidandchoe180arekeybiomarkersinapaneldistinguishingmildfromcriticalcoronavirusdisease2019outcomes AT olonamontserrat fetuinainteratrypsininhibitorglutamicacidandchoe180arekeybiomarkersinapaneldistinguishingmildfromcriticalcoronavirusdisease2019outcomes AT gutierrezvalenciaalicia fetuinainteratrypsininhibitorglutamicacidandchoe180arekeybiomarkersinapaneldistinguishingmildfromcriticalcoronavirusdisease2019outcomes AT buzonmariajose fetuinainteratrypsininhibitorglutamicacidandchoe180arekeybiomarkersinapaneldistinguishingmildfromcriticalcoronavirusdisease2019outcomes AT martianna fetuinainteratrypsininhibitorglutamicacidandchoe180arekeybiomarkersinapaneldistinguishingmildfromcriticalcoronavirusdisease2019outcomes AT gomezbertomeufrederic fetuinainteratrypsininhibitorglutamicacidandchoe180arekeybiomarkersinapaneldistinguishingmildfromcriticalcoronavirusdisease2019outcomes AT auguetteresa fetuinainteratrypsininhibitorglutamicacidandchoe180arekeybiomarkersinapaneldistinguishingmildfromcriticalcoronavirusdisease2019outcomes AT lopezcortesluisf fetuinainteratrypsininhibitorglutamicacidandchoe180arekeybiomarkersinapaneldistinguishingmildfromcriticalcoronavirusdisease2019outcomes AT burgosjoaquin fetuinainteratrypsininhibitorglutamicacidandchoe180arekeybiomarkersinapaneldistinguishingmildfromcriticalcoronavirusdisease2019outcomes AT benaventbofillclara fetuinainteratrypsininhibitorglutamicacidandchoe180arekeybiomarkersinapaneldistinguishingmildfromcriticalcoronavirusdisease2019outcomes AT boquecarme fetuinainteratrypsininhibitorglutamicacidandchoe180arekeybiomarkersinapaneldistinguishingmildfromcriticalcoronavirusdisease2019outcomes AT garciapardograciano fetuinainteratrypsininhibitorglutamicacidandchoe180arekeybiomarkersinapaneldistinguishingmildfromcriticalcoronavirusdisease2019outcomes AT ruizmateosezequiel fetuinainteratrypsininhibitorglutamicacidandchoe180arekeybiomarkersinapaneldistinguishingmildfromcriticalcoronavirusdisease2019outcomes AT mestremariateresa fetuinainteratrypsininhibitorglutamicacidandchoe180arekeybiomarkersinapaneldistinguishingmildfromcriticalcoronavirusdisease2019outcomes AT vidalfrancesc fetuinainteratrypsininhibitorglutamicacidandchoe180arekeybiomarkersinapaneldistinguishingmildfromcriticalcoronavirusdisease2019outcomes AT viladesconsuelo fetuinainteratrypsininhibitorglutamicacidandchoe180arekeybiomarkersinapaneldistinguishingmildfromcriticalcoronavirusdisease2019outcomes AT perairejoaquim fetuinainteratrypsininhibitorglutamicacidandchoe180arekeybiomarkersinapaneldistinguishingmildfromcriticalcoronavirusdisease2019outcomes AT rullanna fetuinainteratrypsininhibitorglutamicacidandchoe180arekeybiomarkersinapaneldistinguishingmildfromcriticalcoronavirusdisease2019outcomes AT fetuinainteratrypsininhibitorglutamicacidandchoe180arekeybiomarkersinapaneldistinguishingmildfromcriticalcoronavirusdisease2019outcomes |